Heron Therapeutics (HRTX)
NASDAQ:HRTX
HRTX Stock Chart & Stats
$0.81
-$0.05(-2.96%)
At close: 4:00 PM EST
$0.81
-$0.05(-2.96%)
Day’s Range― - ―
52-Week Range$0.74 - $2.61
Previous CloseN/A
Volume327.52K
Average Volume (3M)2.26M
Market Cap
$152.81M
Enterprise Value$240.00M
Total Cash (Recent Filing)$46.63M
Total Debt (Recent Filing)$140.64M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding188,537,140
10 Day Avg. Volume2,048,045
30 Day Avg. Volume2,257,910
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)15.12
Price to Sales (P/S)1.40
P/FCF Ratio-7.77
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit2.11
Enterprise Value/Ebitda-19.85
Forecast
1Y Price Target
$4.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$171.73M
Bulls Say, Bears Say
Bulls Say
Commercial InfrastructureCompletion of the vial access needle rollout, pursuit of a potential prefilled syringe, and targeted actions like dedicated product sales teams and distributor incentives create the commercial infrastructure needed to scale Zynrelef and Aponvie.
Reimbursement ProgressPermanent product-specific J-code reimbursement removes a major billing hurdle and should make hospitals and ambulatory surgical centers more comfortable coding and using Zynrelef, supporting broader adoption.
Sales MomentumAnalyst highlights strong sales momentum for Zynrelef that is beginning to drive top-line growth and could attract renewed investor interest as uptake expands.
Bears Say
Formulary Uptake And ExecutionZynrelef is lagging peers in formulary additions and utilization, suggesting institutional inertia and commercial execution shortcomings could slow broader adoption.
Policy And Reimbursement AwarenessMany healthcare providers remain unfamiliar with the NOPAIN Act and related reimbursement rules, which limits current use of non-opioid options like Zynrelef despite policy support.
Product Concentration RiskAnalyst warns that sustained meaningful growth of Zynrelef and Aponvie is critical because legacy CINV products face ongoing pressure, leaving company growth highly dependent on these launches.
Heron Therapeutics News
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $0.74 and its highest was $2.61 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $152.81M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 34 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.02.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 188,537,140 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went up 11.111%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Currently, no hedge funds are holding shares in HRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (455.56% Upside)
$4.50 (455.56% Upside)
Blogger Sentiment
Neutral
HRTX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.17%
12-Months-Change
Fundamentals
Return on Equity
304.91%
Trailing 12-Months
Asset Growth
187.75%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
HRTX Company Deck
HRTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial inflection and financial progress: record annual revenue (~$155M), improved gross margin (~73%), and adjusted EBITDA of $14.7M, alongside clear Q4 momentum in Acute Care driven by ZYNRELEF (+48% YoY) and APONVIE (+97% YoY). Operational wins (financing completion, J-codes, VAN rollout, CrossLink IGNITE, guideline inclusion) support continued growth. Key risks include ongoing Oncology headwinds from the SUSTOL wind-down (7.8% YoY decline in Oncology revenue), pricing pressure and competition for CINVANTI, the multi-year timeline for ZYNRELEF PFS approval, the need to educate providers on the NOPAIN Act, and litigation uncertainty. Management expects to remain EBITDA positive in 2026 while making targeted commercial investments that may temporarily moderate near-term EBITDA but aim to accelerate longer-term revenue and value creation.View all HRTX earnings summariesHRTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(455.56% Upside)
Technical Analysis
Ocugen
―
Benitec Biopharma
―
Kodiak Sciences
―
Sagimet Biosciences, Inc. Class A
―
Neumora Therapeutics, Inc.
―
Ownership Overview
21.29% Insiders
7.95% Mutual Funds
50.90% Other Institutional Investors
11.27% Public Companies and
Individual Investors